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New treatments are needed to protect the myocardium against the detrimental ef-
fects of acute ischaemia/reperfusion (IR) injury following an acute myocardial infarc-
tion (AMI), in order to limit myocardial infarct (MI) size, preserve cardiac function 
and prevent the onset of heart failure (HF). Given the critical role of mitochondria in 
energy production for cardiac contractile function, prevention of mitochondrial dys-
function during acute myocardial IRI may provide novel cardioprotective strategies. In 
this regard, the mitochondrial fusion and fissions proteins, which regulate changes in 
mitochondrial morphology, are known to impact on mitochondrial quality control by 
modulating mitochondrial biogenesis, mitophagy and the mitochondrial unfolded pro-
tein response. In this article, we review how targeting these inter-related processes 
may provide novel treatment targets and new therapeutic strategies for reducing MI 
size, preventing the onset of HF following AMI.
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acute myocardial ischaemia/reperfusion injury, cardioprotection, mitochondrial morphology, 
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1  | INTRODUC TION
Acute myocardial infarction (AMI) and the heart failure (HF) that 
can follow are among the leading causes of death and disability 
worldwide. Although mortality following AMI is on the decline, 
the prevalence and severity of HF is rising. Therefore, new treat-
ments are required to protect the myocardium against the detri-
mental effects of acute ischaemia/reperfusion (IR) injury in order 
to reduce myocardial infarct (MI) size, preserve left ventricular (LV) 
function and prevent the onset of HF.1 Maintenance of healthy 
mitochondria is of critical importance, given the high energy de-
mands required for normal cardiac contractile function.2 Under 
conditions of energy stress such as experienced during acute 
myocardial ischaemia/reperfusion injury (IRI) following AMI, dam-
aged mitochondria generate less ATP and produce reactive oxygen 
species (ROS) that are detrimental to cell survival. As such, new 
therapies that are able to preserve mitochondrial function during 
acute myocardial IRI may provide novel strategies for cardiopro-
tection.2 The mitochondrial fusion and fission proteins have been 
shown to play critical roles in several processes related to mito-
chondrial quality control including mitochondrial biogenesis, mi-
tophagy and the unfolded protein response (UPR). Mitochondrial 
fission is required to selectively remove damaged mitochondria by 
mitophagy (which are then replaced by mitochondrial biogenesis), 
and mitochondrial fusion allows fragmented mitochondria which 
are still viable to re-enter the mitochondrial network (reviewed 
in Refs 2-4). The mitochondrial UPR is a cytoprotective signalling 
pathway triggered by the mitochondrial accumulation of toxic un-
folded proteins under conditions of cellular stress.5 In this article, 
we review how targeting these inter-related processes related to 
mitochondrial quality control may provide novel treatment targets 
and new therapeutic strategies for reducing MI size and prevent-
ing HF following AMI.
2  | MITOCHONDRIAL MORPHOLOGY
Mitochondria are dynamic organelles, constantly changing their 
morphology or shape between a fragmented disconnected phe-
notype by undergoing fission, and an elongated interconnected 
morphology by undergoing fusion, processes which are coordi-
nated by the mitochondrial fission and fusion proteins, respectively 
(Figure 1) (reviewed in Refs 2-4). Mitochondrial fission is essential 
for cell division and is required to remove damaged mitochondria 
by mitophagy. In contrast, mitochondrial fusion enables the replen-
ishment of damaged mitochondrial DNA and facilitates intracellular 
energy distribution. A brief overview of these mitochondrial shaping 
proteins is given here, with the main focus being on their roles in 
acute myocardial IRI, and as potential therapeutic targets for acute 
cardioprotection.
Mitochondrial fission involves the division of a single mitochon-
drion into 2 individual fragmented and disconnected mitochondria 
by the fission proteins, dynamin-related protein 1 (Drp1),6 human 
fission protein 1 (hFis1),7 mitochondrial fission factor (Mff)8 and 
the mitochondrial dynamics proteins of 49 kD (MiD49) and 51 kD 
(MiD51).9,10 During mitochondrial fission, cytosolic Drp1 translo-
cates to the outer mitochondrial membrane (OMM) where it binds 
to the OMM proteins Mff, MiD49, MiD51 and possibly hFis1, at 
pre-constricted sites marked out by contact with endoplasmic 
reticulum (ER).11 Actin polymerization through the ER-localized 
inverted formin 2 (INF2) protein has been shown to mediate the 
mitochondrial pre-constriction process.12,13 Drp1 then oligomer-
izes and forms a helical structure at the site of pre-constriction, 
which encircles and constricts the mitochondrion further, and 
cleaves the mitochondrion into 2 individual mitochondria in a 
GTP-dependent manner.
A number of post-translational modifications have been shown to 
regulate Drp1 function in terms of its subcellular localization and pro-
tein-protein interactions. These include phosphorylation, ubiquiti-
nation, conjugation of small ubiquitin-like modifier (SUMO) proteins 
(SUMOylation), S-nitrosylation, O-linked-N-acetyl-glucosamine gly-
cosylation (O-GlcNAcylation) and most recently acetylation14 (re-
viewed in Ref. 15). Fragmented mitochondria, which have undergone 
fission, have been visualized by electron microscopy of fixed adult 
cardiomyocytes in a number of different cardiac diseases including 
acute myocardial IRI,16 myocarditis,17 stroke,18 doxorubicin cardio-
toxicity,19 sepsis-related cardiomyopathy,20 post-AMI cardiomyop-
athy21 and diabetic cardiomyopathy.22 In this article, we focus on 
the role of the mitochondrial fission proteins as potential therapeutic 
targets for cardioprotection against acute myocardial IRI.
Mitochondrial fusion is characterized by the tethering of two 
adjacent mitochondria via the OMM fusion GTPase proteins, mito-
fusin 1 (Mfn1)23 and mitofusin 2 (Mfn2),24 which then mediate fu-
sion of the OMMs in a GTP-dependent manner. Subsequently, the 
inner mitochondrial membrane (IMM) fusion GTPase protein, optic 
atrophy 1 (OPA1),25,26 mediates fusion of the IMMs resulting in shar-
ing of mitochondrial matrix material, and the formation of a single 
elongated mitochondrion. Importantly, Mfn2 has been reported to 
have a number of non-fusion-related functions including tethering 
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ER to mitochondria,27 mediating mitophagy28 and cellular autoph-
agy,29 and contributing to the stress-related UPR30 (Figures 2 and 
3). Similarly, OPA1 has been demonstrated to play several pleiotro-
pic non-fusion roles related to its effects on cristae remodelling the 
consequences of which are to regulate mitochondrial cytochrome 
release31 and to improve mitochondrial respiratory efficiency by fa-
cilitating the assembly of electron transport supercomplexes.32 In 
addition, OPA1 has been shown to stabilize mitochondrial cristae 
shape and favour ATP synthase oligomerization and needs ATP syn-
thase to protect mitochondria from stress-induced respiratory chain 
inhibition.33 Differentiating the pro-fusion roles of Mfn2 and OPA1 
from their non-fusion roles can be quite challenging and needs to be 
taken into consideration when investigating their roles in the con-
text of acute myocardial IRI and cardioprotection, where both their 
pro-fusion and non-fusion roles may be important.
A number of post-translational modifications have been shown 
to regulate the functions of mitochondrial fusion proteins in terms 
of their proteins levels and protein-protein interactions—these in-
clude phosphorylation (in Mfn1, Mfn2 and OPA1), acetylation (in 
Mfn1, Mfn2 and OPA1), methylation (in Mfn1 and OPA1), and ubiq-
uitination (in Mfn1, Mfn2 and OPA1) (reviewed in Ref. 15). The reg-
ulation of OPA1 has an added layer of complexity given that there 
are 8 splice variants (in humans), and proteolytic processing by mi-
tochondrial proteases, YME1L and OMA1, generates several com-
binations of IMM-anchored long forms of OPA1 (termed L-OPA1) 
which mediate IMM fusion, and soluble short forms of OPA1 within 
the mitochondrial matrix (termed S-OPA1), which contribute to mi-
tochondrial bioenergetics and cristae remodelling (reviewed in Ref. 
26). Reduced levels of cardiomyocyte Mfn2 and OPA1 have been 
observed in a number of cardiac diseases including left ventricular 
hypertrophy,34 post-AMI cardiomyopathy,21,35 myocarditis36 and di-
abetic cardiomyopathy.37 In this article, we focus on the role of the 
mitochondrial fusion proteins as potential therapeutic targets for 
cardioprotection against acute myocardial IRI.
F I G U R E  1   Mitochondrial fission and fusion proteins as targets for cardioprotection. Mitochondrial fission induced by acute myocardial 
ischaemia/reperfusion injury can be targeted by mdivi-1 and Drpitor, pharmacological inhibitors of Drp1 and P110, a peptide inhibitor of the 
interaction between Drp1 and hFis1 to confer cardioprotection. A number of other factors (such as SB203580, PKA activators, succinate, 
erythropoietin and melatonin) have also been shown to confer cardioprotection by targeting the fusion and fission proteins. Inset upper box: 
This scheme shows the mitochondrial fission machinery, comprising Drp1 and its outer mitochondrial membrane receptors, MiD49/MiD51, 
Mff and hFis1. Pre-constriction by the endoplasmic reticulum (ER) via INF2, actin and Spire1C initiates the Drp1-driven mitochondrial fission 
process. Inset lower box: This scheme shows the pleiotropic non-fusion effect of Mfn2 in tethering mitochondria to the ER
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2.1 | Relevance of mitochondrial fission and fusion 
proteins to the adult heart
In adult cardiomyocytes, mitochondria are distributed in 3 main lo-
cations: intermyofibrillar spaces, where they are densely packed and 
mainly provide energy for contractile function (interfibrillar mito-
chondria), just beneath the plasma membrane, where they provide 
energy for the sarcolemmal ion channels (subsarcolemmal mitochon-
dria), and around the nucleus, where they provide energy for nuclear 
transcription (perinuclear mitochondria).38 Because most adult car-
diac mitochondria are fragmented in morphology, and their move-
ment is restricted at these 3 locations, the physiological relevance of 
mitochondrial morphology and dynamics in the adult cardiomyocyte 
has been questioned. However, recent studies have shown that the 
mitochondrial fission and fusion proteins are expressed in the heart 
and are essential for normal foetal cardiac development, as their ge-
netic ablation is embryonically lethal (reviewed in Refs 2-4). Post-
natally, they are also required for normal cardiac development and 
contractile function, as hearts deficient in these proteins develop a 
severe dilated cardiomyopathy (reviewed in Ref. 2-4).
Based on the time course over which fusion-defective mitochon-
drial size decreases in adult mice deficient in both Mfn1 and Mfn2, 
it has been estimated that one mitochondrial fusion/fission cycle in 
adult mouse hearts occurs approximately every 16 days.39 More di-
rect evidence of mitochondrial fusion in adult cardiomyocytes has 
been provided using confocal microscopy imaging of matrix-targeted 
photoactivatable green fluorescent protein of whole rat hearts.40-42 
These studies demonstrated rapid content mixing events between 
adjacent organelles, and slower events between both neighbour-
ing and distant mitochondria, indicative of fusion activity and an 
interconnected mitochondrial network in adult ventricular cardio-
myocytes. Interestingly, mitochondrial fusion activity was shown to 
decrease with culturing the isolated cardiomyocytes due to a decline 
in calcium oscillations/contractile activity,42 such that the fusion 
events are slow, with studies showing that the mitochondrial GFP 
signal takes about 10 hours to spread to the entire population of mi-
tochondria in adult cardiomyocytes.41 These findings raise the pos-
sibility that mitochondrial fusion may actually occur at much faster 
rates in the intact contracting heart.
Deletion of cardiomyocyte Drp1 in the early post-natal period 
resulted in mitochondrial enlargement, increased mitochondrial in-
terconnectivity, decreased mitochondrial respiration, defective mi-
tophagy and a lethal cardiomyopathy at day 7-10 of the post-natal 
period.43,44 Similarly, cardiomyocyte-specific ablation of Drp1 in 
adult mice resulted in a severe cardiomyopathy 4 weeks later when 
compared to wild-type mice with LV dilatation, reduced LV function, 
cardiomyocyte hypertrophy, myocardial fibrosis, increased apopto-
sis, mitochondrial enlargement, impaired mitochondrial respiratory 
function, increased mitochondrial calcium and ROS, and enhanced 
susceptibility to mitochondrial permeability transition pore (MPTP) 
F I G U R E  2   Mitophagy as a target for cardioprotection. The mitochondrial fusion and fission comments have been demonstrated to 
participate in 2 different mitophagy pathways—(A) the PINK-Parkin mitophagy pathway and (B) the Ulk1 mitophagy pathway (modified from 
Ref. 121)
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opening.45-47 Genetic ablation of Mff in mice has been shown to in-
duce a lethal dilated cardiomyopathy at 13 weeks associated with 
increased heterogeneity in mitochondrial shape and abundance, 
perturbed mitochondrial respiratory function, increased myocardial 
apoptosis and interstitial fibrosis.48 Interestingly, this effect was re-
versed if either one of the mitochondrial fusion proteins, Mfn1 or 
Mfn2, were also deleted suggesting that the pro-fusion effect of Mff 
ablation requires the presence of one of the mitofusins. This finding 
also supports the notion that restoring the balance in mitochondrial 
fission and fusion in the heart can normalize cardiac function.48 With 
regard to the mitochondrial fission proteins, MiD49 and MiD51, ge-
netic ablation of these proteins is embryonically lethal,10 but the 
effect of their deletion in the adult heart is not known, and needs 
to be investigated.
With respect to the mitochondrial fusion proteins, cardiomyo-
cyte-specific deletion of Mfn2 resulted in a mild cardiac pheno-
type with modest LVH, mild LV systolic dysfunction, no change 
in mitochondrial respiratory function and unexpected changes in 
mitochondrial morphology and MPTP opening susceptibility, with 
pleomorphic and enlarged subsarcolemmal (but not interfibrillar) 
mitochondria, and resistance to MPTP opening.49 Interestingly, the 
effect of Mfn2 ablation on mitochondrial morphology in neonatal 
rat cardiomyocytes was as expected, with mitochondrial fragmen-
tation and increased susceptibility to MPTP opening, suggesting 
F I G U R E  3   The mitochondrial unfolded 
protein response and cardioprotection. 
Schematic model of the mitochondrial 
unfolded protein response (UPRmt). 
Nicotinamide ribose, ischaemic 
preconditioning (IPC), oligomycin and 
doxycycline are therapeutic strategies 
that have been shown to reduce acute 
myocardial ischaemia/reperfusion injury 
(IRI) by enhancing the UPRmt, and Mfn2 
has been shown to play a key role in the 
UPR
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cell-specific effects on mitochondrial morphology and MPTP open-
ing.49 In addition, to having enlarged mitochondria, Mfn2-deficient 
cardiomyocytes have also being shown by 3D electron microscopy 
to have fewer mitochondria-junctional sarcoplasmic reticulum (SR) 
contacts, and an increase in the distance between mitochondria 
and junctional SR, when compared to wild-type cardiomyocytes.50 
Overexpression of cardiomyocyte-specific Mfn2 in the adult heart 
had a very mild phenotype with minor mitochondrial enlargement 
with no detrimental effects on either mitochondrial respiratory 
function or LV size or function.47 Interestingly, genetic ablation of 
cardiomyocyte-specific Mfn1 did result in smaller more fragmented 
mitochondria, but had no effect on cardiac function or mitochondrial 
respiratory function, although it did prolong time to induce ROS-
mediated MPTP opening.51 The differential effects of Mfn1 versus 
Mfn2 ablation on mitochondrial size may relate to the pleiotropic 
non-fusion effects of Mfn2 such as acting as a tether to the SR.27 The 
mild phenotype observed in hearts deficient in either cardiomyocyte 
Mfn1 or Mfn2 suggests that these proteins have a redundant func-
tion. Genetic ablation of both Mfn1 and Mfn2 mid-gestation resulted 
in a severe cardiomyopathy at day 7 of post-natal period suggesting 
that the mitofusins are needed for the mitochondrial remodelling 
which occurs in the first week following birth.52 Cardiomyocyte-
specific deletion of both Mfn1 and Mfn2 in the adult heart resulted 
in mitochondrial fragmentation, impaired mitochondrial respiration, 
a mitochondrial UFR and a dilated cardiomyopathy.39,46,50,52
Although genetic deletion of OPA1 is embryonically lethal, mice 
with heterozygous ablation of OPA1 survive and have enlarged 
mitochondria with disorganized cristae, increased time to induce 
MPTP opening, but had no effect on cardiac function or mitochon-
drial respiration, although the hearts were more susceptible to LVH 
induced by total aortic constriction.53,54 Heterozygous OPA1 mice 
did however develop a late-onset cardiomyopathy associated with 
fragmented mitochondria with disorganized cristae, impaired mito-
chondrial respiratory function and increased mitochondrial ROS.55 
Genetic mouse models with deletions of OMA1 and/or YME1L (the 
proteases responsible for cleaving L-OPA1 to S-OPA1) have been 
used to investigate the effect of modulating myocardial OPA1 levels 
on mitochondrial morphology, mitochondrial respiratory function 
and cardiac function.56 Genetic deletion of Yme1l in adult cardio-
myocytes was shown to induce mitochondrial fragmentation (due to 
OMA1 cleaving L-OPA1 to S-OPA1), but did not affect mitochondrial 
respiration, and resulted in dilated cardiomyopathy at 20 weeks.56 
Interestingly, additional deletion of OMA1 reversed the detrimental 
effects of YME1L deletion by restoring OPA1 levels.56 These studies 
support an important role for OPA1 in normal cardiac function.
It is interesting and surprising to note that genetic ablation of 
both the mitochondrial fission protein (Drp1),16 and the mitochon-
drial fusion proteins (Mfn1,51 Mfn249 and OPA153,54), had the same 
effect on MPTP opening in adult cardiac mitochondria, with in-
creased resistance to MPTP opening. This finding suggests that the 
mechanisms mediating the changes in MPTP opening susceptibility 
differ between ablation of the fission proteins versus ablation of the 
fusion proteins. The mechanisms through which genetic ablation of 
Drp1 reduces the propensity for MPTP opening is not clear, but may 
relate to the accumulation of factors known to induce MPTP open-
ing such as mitochondrial calcium overload, ROS production and rel-
ative ATP depletion. In contrast, it has been postulated that ablation 
of the outer mitochondrial membrane mitofusin proteins rendered 
cardiac mitochondria resistant to MPTP opening because of their 
potential role in OMM remodelling, which may be associated with 
local perturbations on the integrity of the membrane that predis-
pose to MPTP opening,49,57 although further studies are needed to 
confirm this. The mechanisms through which partial ablation of the 
inner mitochondrial membrane fusion protein, OPA1, limits MPTP 
opening susceptibility are not clear, although it has been postu-
lated that partial loss of OPA1 may disturb the organization of the 
inter-membrane space and contact points between the outer and 
inner mitochondrial membranes, and modulate the susceptibility of 
MPTP opening through this mechanism.53,54
In summary, genetic deletion of the mitochondrial fission (Drp1, 
Mff) or fusion proteins (Mfn2, OPA1) induce changes in mitochon-
drial morphology, impair mitochondrial respiration and result in di-
lated cardiomyopathy, confirming that these proteins are essential 
for normal cardiac development and contractile function.
2.2 | Potential mechanisms underlying IR-induced 
mitochondrial fission
In 2006, Brady et al58 made the interesting observation that simu-
lated ischaemia in the HL-1 cardiac cell line induced a change in mito-
chondrial morphology from an elongated phenotype to a fragmented 
one, a change which persisted into simulated reperfusion. Subsequent 
studies have confirmed that mitochondria undergo Drp-1-mediated 
mitochondrial fission in neonatal and adult rodent hearts.16
The mechanisms through which IR induces mitochondrial fission 
are not clear but a number of factors may play a role: (a) oxidative 
stress—this is increased in acute myocardial IRI and is known to be an 
inducer of mitochondrial fission59; (b) p38 MAPK—pharmacological in-
hibition of p38 MAPK at reoxygenation in HL-1 cells has been shown to 
reverse hypoxia-induced mitochondrial fragmentation, suggesting that 
p38 MAPK activation may in part contribute to hypoxia/reoxygen-
ation-induced mitochondrial fission58; (c) Cdk1 and PKC-δ—these have 
been shown to increase during IRI and associate with Drp1, thereby in-
ducing mitochondrial fission59; (d) calcium overload—this occurs in IRI 
and has been shown to induce mitochondrial fission60; (e) calcineurin—
IRI has been shown to induce calcineurin activation, which is known to 
dephosphorylate Drp1 at Ser637, thereby promoting translocation of 
Drp1 to mitochondria to induce fission.59,61 Wang et al61 have demon-
strated that miRNA499 was shown to confer cardioprotection by pre-
venting IR-induced calcineurin activation and inhibiting Drp1-mediated 
fission; (f) SUMOylation of Drp1—it has been reported that Sentrin-
specific protease 3 (SENP3)-mediated deSUMOylation of Drp1 facil-
itated its binding to Mff and promoted cell death following simulated 
IRI62,63; (g) succinate—it has been shown that extracellular succinate 
produced during acute myocardial IRI activated GPR91 and promoted 
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mitochondrial fission by inducing the translocation of Drp1 via PKC-
δ, and the phosphorylation of Mff via Erk1/264; (h) myocardial levels 
of dual-specificity protein phosphatase1 (DUSP1), an anti-apoptotic 
phosphatase, are reduced following acute myocardial IRI, and it has 
been shown that mice overexpressing DUSP1 were protected against 
Mff-induced mitochondrial fission and BNIP-mediated mitophagy and 
had reduced MI size, when compared to control65; (i) nuclear recep-
tor subfamily 4 group A member 1 (NR4A1) has been reported to be 
up-regulated following acute myocardial IRI and induce mitochondrial 
fission and suppress mitophagy via casein kinase2 α (CK2α)-mediated 
phosphorylation of Mff and FUN14 domain-containing 1 (FUNDC1), 
respectively.66 Mice deficient in NR4A1 were demonstrated to be pro-
tected against acute coronary microvascular injury and mitochondrial 
dysfunction, when compared with wild-type mice.66
In summary, a number of different factors have been shown to con-
tribute to the observed mitochondrial fission which occurs in response 
to acute myocardial IRI, thereby providing multiple therapeutic targets 
for inhibiting mitochondrial fission as a cardioprotective strategy.
2.3 | Therapeutic targeting of the mitochondrial 
fission proteins for cardioprotection
It has been shown in HL-1 cardiac cells that transfection with Drp1 
dominant-negative mutant-induced mitochondrial elongation pre-
vented MPTP opening and reduced cell death following simulated 
IRI,16 demonstrating Drp-1 mediated mitochondrial fission to be 
a therapeutic target for cardioprotection. In this regard, it has 
been shown that acute inhibition of mitochondrial fission using 
the putative Drp1 GTPase inhibitor, mitochondrial division inhibi-
tor 1 (mdivi-1), reduced cell death in isolated adult murine cardio-
myocytes subjected to simulated IRI and reduced MI size in murine 
hearts subjected to in vivo acute myocardial IRI.16 Mdivi-1 has also 
been shown to inhibit IR-induced mitochondrial fragmentation in 
a diabetic mouse model of acute myocardial IRI67 and inhibited 
mitochondrial fission and restored the cardioprotective effects 
of sevoflurane under conditions of high glucose in neonatal rat 
cardiomyocytes.68 It has also been demonstrated that mdivi-1 re-
duced cell death in human W8B2+ cardiac stem cells subjected to 
simulated IRI, although in that study no beneficial effects were 
observed on mitochondrial morphology so the mechanisms under-
lying the cardioprotective effect in these cells are unclear.69 Other 
pharmacological inhibitors of mitochondrial fission have also been 
shown to be cardioprotective including Dynasore (a non-specific 
inhibitor of dynamins),70 and P110, a peptide inhibitor that inhibits 
the interaction between Drp1 and hFis.71 Importantly, pharma-
cological inhibition of mitochondrial fission at the onset of rep-
erfusion, a clinically relevant time-point, using either P11071 or 
mdivi-172 was shown to reduce MI size in small animal models of 
acute myocardial IRI. In Table 1, we present a summary of the main 
experimental studies investigating cardioprotection with pharma-
cological agents targeting mitochondrial fission proteins.
Recent studies suggest that mdivi-1 has off-target effects that 
are independent of its inhibitory effects on Drp1 GTPase activity, 
TA B L E  1   Summary of major studies investigating cardioprotection with pharmacological agents targeting mitochondrial fission proteins
Mitochondrial fission 
and fusion protein Pharmacological agent
Animal acute 
myocardial IRI models Cardioprotective effect Comment
Drp116 Mdivi-1, pre-treatment In vivo mouse heart Reduced MI size and less 
fission
 
Drp167 Mdivi-1, 15 min prior to 
reperfusion




Drp181 Mdivi-1, alone or in 
nanoparticles at 
reperfusion
Ex vivo mouse heart Both mdivi-1 alone or in 
nanoparticles reduced MI size
Mdivi-1 delivered by 
nanoparticles more 
cardioprotective.
Drp181 Mdivi-1, alone or in 
nanoparticles at 
reperfusion
In vivo mouse heart Mdivi-1 only reduced MI 
size when delivered by 
nanoparticles
Mdivi-1 delivered by 
nanoparticles more 
cardioprotective.
Drp180 Mdivi-1, at reperfusion In vivo closed-chest pig 
heart
No reduction in MI size or 
change in mitochondrial 
morphology
Underpowered study.
Drp170 Dynasore, during 
reperfusion
Ex vivo mouse heart Reduced MI size  
hFis1-Drp1 interaction71 P110 in stabilization and 
during reperfusion
Ex vivo rat heart Reduced MI size  
hFis1-Drp1 interaction71 P110 at reperfusion In vivo rat heart Reduced MI size  
Drp175 Drpitor1 and Drpitor1a 
pre-treatment
Ex vivo rat heart Improved right ventricle 
function, less fission and 
mitochondrial ROS production
 
Abbreviation: MI, myocardial infarct.
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including it being a weak and reversible inhibitor of complex I, and 
modulating mitochondrial production of ROS in neurons,73 and in-
hibiting complex II, and modulating transient opening of the MPTP 
in isolated adult cardiomyocytes.74 Novel, more specific inhibitors 
of Drp1 itself or its interaction with its OMM receptors, Mff and 
MiD49/MiD51, would provide more effective cardioprotection and 
facilitate the translation of acute mitochondrial fission inhibition as 
a cardioprotective strategy. In this regard, Wu et al75 have identified 
2 novel Drp1 inhibitors (Drpitor1 and Drpitor1a) which have been 
shown to be more potent and specific than mdivi-1 in terms of inhib-
iting Drp1 GTPase activity (without complex I inhibition), and which 
conferred cardioprotection against acute IRI in the isolated perfused 
rat heart when given as a pre-treatment.
Genetic inhibition of Drp1 using either siRNA61 or Drp1 dom-
inant-negative K38A mutant76 has been shown to prevent trans-
location of Drp1 to mitochondria, reduce cell death in isolated 
rat cardiomyocytes subjected to IRI and reduce MI size in rat 
hearts subjected to in vivo acute IRI. With respect to the other 
mitochondrial fission protein, Mff, it has been reported that Mff 
levels increase in neonatal rat cardiomyocytes subjected to hy-
drogen peroxide,77 and in murine hearts subjected to acute IRI.78 
Importantly, siRNA ablation of Mff prevented hydrogen perox-
ide-induced mitochondrial fission, and siRNA knockdown of Mff 
also reduced MI size in the adult mouse heart subjected to acute 
IRI.77 In addition, adult mice deficient in Mff (by gene trap) have 
been reported to have smaller MI size, and better cardiac function 
compared to wild-type mice.78 The role of the mitochondrial fis-
sion proteins, MiD49 and MiD51 has not been studied as potential 
targets for cardioprotection, although they have been reported to-
gether with Drp1 to mediate mitochondrial division that is needed 
for vascular smooth muscle cell proliferation in pulmonary arterial 
hypertension (PAH) animal models,79 positioning mitochondrial 
fission as a therapeutic target for PAH.
Taken together, these findings demonstrate mitochondrial fis-
sion to be a target for cardioprotection in rodent models of acute 
myocardial IRI, and the next step in the translational pathway is to 
test the efficacy of this therapeutic approach in a large animal AMI 
model. In this regard, a recent small pilot study has tested the car-
dioprotective effects of mdivi-1 administered as an intracoronary 
bolus immediately prior to reperfusion in the clinically relevant 
closed-chest pig AMI model. However, it found no difference in 
MI size, LV systolic function, myocardial fibrosis or mitochondrial 
morphology after 3 days reperfusion when compared to vehicle 
control.80 Potential reasons for the lack of cardioprotection in-
clude the small sample size, potential off-target effects of mdivi-1 
and insufficient delivery of mdivi-1 into the ischaemic myocar-
dium in the first few minutes of reperfusion. In terms of the latter 
issue, it has been shown that nanoparticle delivery of mdivi-1 to 
the ischaemic heart enhanced its cardioprotective effect in terms 
of MI size reduction in the murine AMI model,81 and nanoparticle 
delivery of mdivi-1 to the ischaemic heart may be more effective 
in the pig AMI model. Furthermore, it would be interesting to in-
vestigate whether more specific inhibitors of the mitochondrial 
fission machinery such as P11071 may be more effective in this 
large animal AMI model.
The beneficial effects of inhibiting mitochondrial fission have 
also been investigated in the coronary microvasculature following 
acute myocardial IRI, a neglected target for cardioprotection.82 
Melatonin, a well-established cardioprotective factor, has been 
shown to reduce coronary microvascular injury, as evidenced by 
preserved endothelial integrity, increased endothelial nitric oxide 
synthase (eNOS) expression, less lumen obstruction, attenuated 
inflammatory cell infiltration and less endothelial cell death, find-
ings which were associated with reduced mitochondrial fission 
and less MPTP opening in coronary endothelial cells.83 Similarly, 
the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagli-
flozin84 and Bax inhibitor 1 (BI1)85 have been reported to reduce 
coronary microvascular injury by inhibiting mitochondrial fission 
via the Syk–Nox2-Drp1 signalling pathway. Finally, mice deficient 
in Mff have been reported to be protected against IRI to the cor-
onary microvasculature an effect which was attributed to less mi-
tochondrial fission, attenuated cardiolipin oxidation and apoptosis 
and inhibition of MPTP opening (via blocking the oligomerization 
of VDAC1 and HK-2 separation from mitochondria) in coronary 
microcirculation endothelial cells.78 These findings support the 
notion that therapeutic inhibition of mitochondrial fission may 
accrue dual benefits against acute myocardial IRI with cytopro-
tective effects on both cardiomyocytes and the coronary micro-
vasculature. In other organs, such as kidney86 and brain,18 acute 
IRI has also been shown to induce mitochondrial fragmentation, 
with genetic and pharmacological inhibition of Drp1 also confer-
ring protection.
In summary, experimental small animal studies have provided 
convincing evidence that acute inhibition of mitochondrial fission 
is cardioprotective, and novel more specific inhibitors of the fission 
machinery are needed to translate this therapeutic strategy for pa-
tient benefit. However, although acute inhibition of mitochondrial 
fission has been shown to be cardioprotective, chronic inhibition of 
fission is known to be detrimental, with cardiomyocyte-specific ge-
netic deletion of Drp145 increasing susceptibility to acute myocardial 
IRI, an observation which most likely relates to the suppression of 
mitophagy, resulting in accumulation of damaged mitochondria and 
the development of cardiomyopathy (see Section 3). These findings 
underscore the importance of balancing mitochondrial fusion and 
fission for normal cardiac function.
2.4 | Other cardioprotective interventions targeting 
IR-induced mitochondrial fission
A number of established cardioprotective interventions, treatments 
and factors have been shown to mediate their beneficial effects via 
inhibition of mitochondrial fission and preservation of mitochondrial 
function, following acute myocardial IRI. These include (a) aerobic 
interval training87; (b) nitrite pre-treatment, which has been shown 
to activate PKA which in turn phosphorylates Drp1 at Ser637, 
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thereby preventing IR-induced mitochondrial fission88; (c) chronic 
therapy with the SGLT2 inhibitors, either empagliflozin89 or dapa-
gliflozin,90 therapies which have been shown to improve cardiovas-
cular outcomes, have been demonstrated to inhibit mitochondrial 
fission and reduce MI size in rodent models of acute myocardial IRI; 
(d) zinc, a known cardioprotective agent, was reported to mediate 
SUMOylation of Drp1 thereby inhibiting mitochondrial fission and 
reducing MI size in the mouse heart91; (e) proto-oncogene serine/
threonine protein kinase (PIM-1) has been shown to reduce mito-
chondrial translocation of Drp1 and inhibit mitochondrial fission 
following acute myocardial IRI92; (f) vagal nerve stimulation which 
is a known cardioprotective strategy has been shown to inhibit mi-
tochondrial fission, preserve mitochondrial function and prevent 
MPTP opening in acute myocardial IRI small animal models93,94; (g) 
Parkinson's disease-related mitochondrial protein, DJ-195 has been 
shown to protect the heart by regulating the SUMOylation status 
of Drp1, thereby attenuating IR-induced mitochondrial fission96; (h) 
ginsenoside Rg5 has been shown to activate Akt and mitochondrial 
hexokinase II, thereby attenuating the translocation of Drp-1 to mi-
tochondria and inhibiting fission in an isoproterenol (ISO)-induced 
acute myocardial IRI mouse model97; (i) isosteviol sodium, a compo-
nent of artificial sweetners, has been shown to inhibit mitochondrial 
fission and reduce MI size in the isolated guinea pig heart subjected 
to acute IRI98; (j) miRNA763 has been demonstrated to inhibit Mff-
induced mitochondrial fission and reduced MI size in a mouse acute 
IRI model77; and finally (k) propofol has been reported to inhibit mi-
tochondrial fission and reduce cell death in H9C2 cells subjected to 
simulated IRI.99
In summary, these studies implicate IR-induced mitochondrial 
fission to be a critical mediator of cardiomyocyte death following 
AMI that can be targeted indirectly via a wide variety of cardiopro-
tective agents.
2.5 | Targeting mitochondrial fusion proteins for 
cardioprotection
Given the data supporting mitochondrial fission to be a key deter-
minant of cardiomyocyte death following acute IRI, studies have 
explored the effect of promoting mitochondrial fusion as a target 
for cardioprotection. However, as mentioned previously, the in-
terpretation of these studies can be quite challenging given the 
pleiotropic non-fusion functions of Mfn2 and OPA1, which may 
also contribute to cardioprotection. An early study in COS-7 cells 
demonstrated that activating Mfn2 protected cells against apop-
totic cell death and ROS-induced MPTP opening.100 In contrast to 
this study, it has been shown that overexpressing Mfn2 in neona-
tal cardiomyocytes increased apoptotic cell death.101 In HL-1 car-
diac cells, it has been reported that overexpressing either Mfn1 or 
Mfn2 prevented IR-induced mitochondrial fragmentation, inhibited 
MPTP opening and reduced cell death following simulated IRI.16 
In addition, activation of the cardioprotective kinase, Akt, by ei-
ther genetic activation or erythropoietin has been shown to induce 
mitochondrial elongation via Mfn1, inhibit MPTP opening and pro-
tect the heart against acute IRI.102
In the adult heart, the effects of modulating cardiomyocyte 
mitofusins have produced unexpected effects in terms of suscepti-
bility to acute IRI. Adult mouse studies have reported that isolated 
cardiomyocytes lacking Mfn1 displayed mitochondrial fragmenta-
tion and were protected against hydrogen peroxide-induced MPTP 
opening and cell death.51 Similarly, cardiomyocyte-specific deletion 
of Mfn2 in the adult heart induced a modest LVH associated with 
pleomorphic enlargement of mitochondria, and inhibition of MPTP 
opening, and increased resistance to acute myocardial IRI.49 The 
mechanisms underlying the cardioprotective effects of individual 
Mfn1 and Mfn2 cardiomyocyte ablation were not clear from these 
studies. Interestingly, it has been shown that deletion of both Mfn1 
and Mfn2 in the adult heart inhibited MPTP opening and reduced MI 
size,50 a cardioprotective effect which was attributed to the pleio-
tropic non-fusion role of Mfn2 in tethering mitochondria to the sar-
coplasmic reticulum to create localized microdomains through which 
calcium can transit.27,103 Depletion of cardiomyocyte mitofusins 
was demonstrated to confer cardioprotection by reducing tether-
ing of mitochondria to SR and attenuating IR-induced mitochondrial 
calcium overload and MPTP opening.50 Therefore, targeting Mfn2 
during acute myocardial IRI to transiently disassociate mitochondria 
from SR may provide a novel cardioprotective strategy. In this re-
gard, Franco et al104 have engineered cell-permeant mini-peptides 
with the ability to destabilize the fusion-constrained conformation 
of mitofusin (thereby inhibiting Mfn2) and promote the fusion-per-
missive conformation (thereby activating Mfn2), but their effect on 
mitochondrial morphology and susceptibility to acute IRI in the adult 
heart remains to be tested.
With respect to the mitochondrial fusion protein, OPA1, stud-
ies have investigated its role as a cardioprotective target, but as 
with Mfn2, attributing the cardioprotective effects of OPA1 to its 
pro-fusion function has been challenging, given its potential cardi-
oprotective non-fusion effects on mitochondrial cristae remodel-
ling that prevent apoptosis and facilitate the assembly of electron 
transport supercomplexes and improve mitochondrial respiratory 
efficiency. Chen et al35 showed reduced myocardial levels of OPA1 
and mitochondrial fragmentation in both rat and human models 
of heart failure, and demonstrated in H9C2 cells that simulated 
IR reduced levels of OPA1, and siRNA ablation of OPA1 induced 
mitochondrial fragmentation, and increased susceptibility to 
IRI. Recently, it has been shown in human atrial tissue obtained 
from patients undergoing cardiac bypass surgery that myocardial 
L-OPA1 levels were decreased and this was associated with mito-
phagy and mitochondrial biogenesis from the IRI stress of heart 
surgery.105 Le Page et al54 have shown that OPA1± mice (which 
have a 30% reduction in OPA1 levels) were more susceptible to 
acute myocardial IRI, although this effect was not associated with 
changes in mitochondrial morphology, mitochondrial respiratory 
function, apoptosis or MPTP opening, and so the mechanisms un-
derlying this cardioprotective effect are not clear from this study. 
In contrast, it has been shown in the adult mouse that genetic 
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overexpression of OPA1 stabilized mitochondrial cristae thereby 
improving mitochondrial respiratory efficiency, preventing mito-
chondrial dysfunction, attenuating cytochrome c release and ROS 
production, and through these actions, it reduced susceptibility 
to acute myocardial IRI.106 However, the effect of OPA1 overex-
pression on preventing IR-induced mitochondrial fragmentation 
was not assessed, as the cardioprotective effects of OPA1 were 
attributed to its non-fusion effects on mitochondrial cristae re-
modelling and improving mitochondrial respiratory efficiency. 
Importantly, in this mouse model of OPA1 overexpression, there 
were beneficial effects in other organs with protection from mus-
cular atrophy, brain ischaemia and liver apoptosis.106
Interestingly, the role of OPA1 as a cardioprotective target has been 
investigated in the context of remote ischaemic conditioning (RIC), an 
endogenous cardioprotective strategy in which cycles of brief non-le-
thal ischaemia and reperfusion applied to the limb increase resistance 
to a sustained episode of lethal acute myocardial IRI.107-109 These au-
thors showed that using a tourniquet to induce four- to 5-minute cycles 
of hindlimb ischaemia and reperfusion reduced MI size, and this was 
associated with less mitochondrial fragmentation and preservation of 
myocardial OPA1 levels without affecting levels of Mfn2.109 Further 
studies are needed to investigate whether RIC increased myocardial 
OPA1 levels by suppressing stress-induced activation of OMA1. The 
cardioprotective agent, melatonin, has recently been demonstrated 
to confer cardioprotection via AMPK-OPA1 as evidenced by reduced 
MI size, inhibition of IR-induced mitochondrial fission, preservation of 
mitochondrial respiratory function, less MPTP opening and decreased 
apoptosis.110 Similarly, the brain-derived neurotrophic factor mimetic, 
7,8-dihydroxyflavone, has been reported to confer cardioprotec-
tion via inhibition of IR-induced mitochondrial fission and decreased 
apoptosis.111 Finally, modulation of OPA1 levels by genetic ablation of 
OMA1 has also been shown to protect against acute renal IR acute in-
jury.112 In terms of therapeutic targeting of OPA1 as a cardioprotective 
strategy, a recent study has identified epigallocatechin gallate to be a 
novel pharmacological inhibitor of OMA1. Treatment of mouse embry-
onic fibroblasts was able to prevent cleavage of L-OPA1 to S-OPA1, 
inhibit mitochondrial fission, prevent apoptosis and reduce cell death 
following simulated IRI, providing a potential therapeutic strategy for 
reducing MI size following acute myocardial IRI.
In summary, these studies implicate the mitochondrial fusion 
proteins, Mfn2 and OPA1, to be potential targets for cardioprotec-
tion, but the mechanisms underlying their beneficial effects appear 
to be related to their non-fusion pleiotropic functions rather than 
their pro-fusion effects.
3  | TARGETING MITOPHAGY FOR 
C ARDIOPROTEC TION
Under basal conditions, mitophagy is required for mitochondrial 
quality control and plays a key role in removal of damaged mitochon-
dria.113 Mitophagy is activated during acute myocardial IRI, where 
it appears to protect the heart against cell death, as it preserves 
energy substrates, removes damaged mitochondria and attenuates 
oxidative stress. In this regard, it has been shown that inhibition of 
mitophagy in mice deficient in cardiomyocyte Drp145 or PGAM5114 
or treatment with bicarbonate115 increased cell death following 
acute IRI. In contrast, activation of mitophagy prior to acute myo-
cardial ischaemia, by cardioprotective strategies such as ischaemic 
preconditioning116 and simvastatin,117 has been shown to reduce 
myocardial infarction size following acute myocardial IRI. It has also 
been shown that mitophagy activation occurs in human heart tis-
sue harvested from patients subjected to acute myocardial IRI dur-
ing cardiac surgery and is associated with increases in mitochondrial 
biogenesis, where it promotes turnover of cardiac mitochondria.105
The canonical PINK-Parkin pathway for homeostatic mito-
phagic mitochondrial quality control was originally defined by 
genetic manipulation of these two factors in Drosophila fruit 
flies,118,119 establishing the mitophagy mechanistic link between 
the mitochondria-localized kinase, PINK and the downstream cy-
tosolic E3-ubiquitin ligase, Parkin (Figure 2). Contrasting with the 
situation in normal hearts wherein Parkin is barely detectable and 
functionally dispensable, Parkin is transcriptionally up-regulated in 
different forms of cardiac stress where it plays an important role 
in the mitophagic response.46,120,121 Compared to wild-type mice, 
Parkin-deficient mice had disorganized mitochondrial networks and 
smaller mitochondria, although mitochondrial and cardiac function 
were unaffected.120 However, the Parkin-/- mice were more sus-
ceptible to acute myocardial IRI and had reduced survival and mi-
tophagy with accumulated swollen, dysfunctional mitochondria 
after  infarction.120 In contrast, overexpression of Parkin in isolated 
cardiomyocytes protected against simulated ischemic injury.120 A 
cardioprotective role for PINK1 kinase has also been observed in a 
mouse AMI model.122 These data suggest cardioprotective effects 
of the PINK-Parkin mitophagy pathway in the setting of acute myo-
cardial IRI.
Drp1-mediated mitochondrial fission generates fragmented 
mitochondria for selective removal by Parkin-induced and Bnip3-
induced mitophagy123,124 as a key strategy for maintaining mitochon-
drial quality control. It has been shown that siRNA ablation of Drp1 
in neonatal ventricular rat cardiomyocytes induced mitochondrial 
elongation, increased apoptosis, suppressed autophagic flux, result-
ing in accumulation of dysfunctional mitochondria and increased 
MPTP opening.45 Overexpression of Drp1 in cardiomyocytes in-
duced mitochondrial fragmentation, enhanced autophagic flux and 
increased apoptotic cell death.45 Cardiomyocyte-specific ablation 
of Drp1 in adult mice at 12 weeks of age induced cardiomyocyte 
hypertrophy and a lethal dilated cardiomyopathy with mitochondrial 
elongation, increased apoptosis, suppressed autophagic flux, accu-
mulation of dysfunctional mitochondria and increased MPTP open-
ing.45 Interestingly, both heterozygous Drp1 mice and mice with 
cardiomyocyte-specific ablation of Drp1 in adult mice increased MI 
size, suggesting that chronic Drp1 ablation and perturbed mitophagy 
increases susceptibility to acute myocardial IRI,45 which differs from 
acute inhibition of mitochondrial fission which has been shown to be 
cardioprotective.16
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Mfn2 involvement in mitophagy is contextually complex, re-
cruiting Parkin to mitochondria for normal perinatal metabolic 
remodelling,28,125 controlling mitochondrial quantity in normal 
adult hearts46,126 and mediating stress-induced calcium signalling 
between cardiomyocyte ER and mitochondria.127-129 How these 
different mechanisms of mitofusin-involved mitophagy overlap, 
complement or compete with each other and with other mitophagy 
pathways remains incompletely understood. Interestingly, Mfn2 has 
also be reported to be required for cardiac autophagy, by potentially 
functioning as an adaptor on ER-derived autophagosome membrane 
for RAB7, a autophagosome maturation-related protein, to mediate 
the fusion of autophagosomes with lysosomes.29 Mice deficient in 
cardiomyocyte Mfn2 were shown to accumulate autophagosomes 
due to impaired fusion of autophagosomes with lysosomes, resulting 
in impaired mitochondrial function, slightly enlarged mitochondria 
and increased susceptibility to acute myocardial IRI,29 suggesting an 
important role for Mfn2-mediated autophagy as a cardioprotective 
target.
Recently, a novel PINK/Parkin-independent pathway of mi-
tophagy has been described which functions under conditions 
of energy stress including starvation and acute myocardial IRI130 
(Figure 2). This is based on a protein complex consisting of unc-51-
like kinase 1 (Ulk1), Rab9, receptor-interacting serine/threonine 
protein kinase 1 (RIP1) and Drp1, which allows the recruitment 
of trans-Golgi membranes associated with Rab9 to damaged mi-
tochondria through phosphorylation of Rab9 at S179 by Ulk1 
and phosphorylation of Drp1 at S616 by RIP1.130 This novel 
Ulk1/Rab9/Rip1/Drp1 mitophagy pathway was shown to protect 
the heart against acute myocardial IRI by maintaining healthy 
mitochondria.130
In summary, enhancing mitophagy during acute myocardial IRI is 
an important strategy for cardioprotection. Given the close interplay 
between mitochondrial morphology and mitophagy, therapeutic tar-
geting of the mitochondrial fission and fusion proteins may provide a 
strategy for boosting mitophagy following AMI.
4  | TARGETING THE MITOCHONDRIAL 
UNFOLDED PROTEIN RESPONSE FOR 
C ARDIOPROTEC TION
The mitochondrial UPR (UPRmt) is a cytoprotective signalling path-
way triggered by the mitochondrial accumulation of toxic unfolded 
proteins under conditions of cellular stress that induces mitochon-
drial dysfunction (Figure 3). The UPRmt, in turn, up-regulates cy-
clic AMP-dependent transcription factor ATF-5 (ATF5) to restore 
mitochondrial proteostasis and respiratory function.131 The mito-
chondrial fusion protein, Mfn2, which is known to tether mitochon-
dria to the ER, has been shown to regulate the UPR. Ngoh et al30 
showed that ER stress induced the gene and protein expression of 
Mfn2 but not Mfn1, with ablation of Mfn2 (but not Mfn1) in adult 
murine cardiomyocytes exacerbating ER stress-mediated apoptotic 
cell death. It has been shown that Mfn2 regulates the UPR and mi-
tochondrial respiratory function by down-regulating protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), an ER stress-related 
protein.132 Adult mice deficient in cardiomyocyte Mfn2 have also 
been shown to have increased ER stress (as evidenced by increased 
expression of ER stress-related genes Asns, Atf4, Trib3, Chop, ATF6, 
and Gsta1), supporting a role for Mfn2 in preventing ER stress in the 
adult heart.29 The role Mfn2 plays specifically in UPRmt remains to 
be established. The UPRmt has recently been demonstrated to occur 
in heart diseases such as cardiac failure,133 pressure overload134 and 
acute myocardial IRI,5 making it an attractive therapeutic target for 
cardioprotection.
It has been shown in mice hearts subjected to pressure-over-
load hypertrophy and in hypertrophied human heart tissue due 
to aortic stenosis, that the UPRmt is increased as evidenced by 
up-regulation of ATF5 and the C/EBP transcription factor CCAT-
enhancer-binding protein homologous protein (CHOP), which 
encodes adaptive proteins of the UPRmt.134 Importantly, from a 
therapeutic perspective, it was reported that the UPRmt could 
be enhanced using nicotinamide riboside (which augments NAD+ 
pools) in cardiomyocytes and prevented cardiomyocyte death 
and preserved mitochondrial respiratory function and cardiac 
contractile function.134 Pharmacological induction of the UPRmt 
using either oligomycin or doxycycline reduced MI size in wild-
type mice but not ATF5-deficient mice, suggesting that ATF5-
mediated UPRmt confers cardioprotection against acute IRI.5 The 
mitochondrial protease, LonP1, which ensures mitochondrial pro-
teostasis and regulates adaptive responses to cell stress, has been 
shown to contribute to the cardioprotection elicited by ischaemic 
preconditioning (IPC), an endogenous cardioprotective interven-
tion in which brief cycles of non-lethal ischaemia and reperfusion 
protect the heart against an episode of acute lethal IRI.135 IPC 
was shown to up-regulate LONP1 in wild-type mice, and hetero-
zygous LONP1± mice were shown to be more susceptible to acute 
myocardial IRI as evidenced by mitochondrial dysfunction and in-
creased MI size, and were found to be resistant to IPC-induced 
cardioprotection.136 In contrast, genetic overexpression of car-
diomyocyte-specific LONP1 prevented IR-induced mitochon-
drial dysfunction and reduced MI size, implicating mitochondrial 
LONP1 as an endogenous mediator of cardioprotection.136
In summary, enhancing the UPRmt during acute myocardial IRI 
has emerged as a novel therapeutic cardioprotective strategy. 
Although pharmacological strategies such as nicotinamide riboside, 
oligomycin and doxycycline have been shown to confer cardiopro-
tection by enhancing the UPRmt, novel more specific activators of 
the UPRmt are needed.
5  | CONCLUSIONS
Preventing mitochondrial dysfunction during acute myocardial IRI 
following AMI is a major therapeutic strategy for cardioprotection 
6582  |     HERNANDEZ-RESENDIZ Et Al.
in terms of reducing MI size, preserving cardiac function and pre-
venting the onset of HF. In this regard, the mitochondrial fission 
and fusion proteins which play key roles in process involved in 
mitochondrial quality control (such as mitochondrial morphology, 
mitophagy and UPRmt), act to preserve normal mitochondrial res-
piratory function in the setting of acute myocardial IRI, positioning 
them as key targets of cardioprotection. Substantial experimental 
data suggest that acute inhibition of mitochondrial fission can re-
duce MI size and preserve cardiac function in small animal models 
of AMI. Further studies are needed to test this therapeutic ap-
proach in clinically relevant large animal AMI models and to dis-
cover novel more specific inhibitors of the mitochondrial fission 
machinery. However, it is important to note that chronic inhibi-
tion of mitochondrial fission is detrimental to both susceptibility 
to acute IRI and cardiac function, as it suppresses mitophagy and 
results in the accumulation of damaged mitochondria. Although 
the mitochondrial fusion protein, OPA1, has been shown to be 
a target for acute cardioprotection (with its overexpression pro-
tecting against acute myocardial IRI), its beneficial effects have 
been attributed to non-fusion pleiotropic roles rather than its 
effects on mitochondrial morphology. The role of the mitofusins 
as targets for acute cardioprotection has been unexpected, as it 
appears that ablation of Mfn1 and/or Mfn2 confers a protective 
response against acute myocardial IRI, and again this may be due 
to their non-fusion pleiotropic roles (such as tethering SR), rather 
than their effects on mitochondrial morphology. Overall, target-
ing the mitochondrial fusion and fission proteins have emerged as 
important targets for cardioprotection and have the therapeutic 
potential to reduce MI size, preserve cardiac function and prevent 
HF in patients presenting with AMI.
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